Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

New Zealand's drug development industry.

Lockhart MM, Babar ZU, Carswell C, Garg S.

Int J Environ Res Public Health. 2013 Sep 13;10(9):4339-51. doi: 10.3390/ijerph10094339. Review.

PMID:
24065037
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

New Zealand's drug development industry--strengths and opportunities.

Lockhart MM, Babar ZU, Garg S.

N Z Med J. 2010 Jun 25;123(1317):52-8.

PMID:
20657631
[PubMed - indexed for MEDLINE]
3.

Evaluation of policies to support drug development in New Zealand.

Lockhart M, Babar ZU, Garg S.

Health Policy. 2010 Jul;96(2):108-17. doi: 10.1016/j.healthpol.2010.01.012. Epub 2010 Feb 18. Review.

PMID:
20170976
[PubMed - indexed for MEDLINE]
4.

Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.

DiMasi JA, Hansen RW, Grabowski HG, Lasagna L.

Pharmacoeconomics. 1995 Feb;7(2):152-69.

PMID:
10155302
[PubMed - indexed for MEDLINE]
5.

How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL.

Nat Rev Drug Discov. 2010 Mar;9(3):203-14. doi: 10.1038/nrd3078. Epub 2010 Feb 19.

PMID:
20168317
[PubMed - indexed for MEDLINE]
6.

Funding of Parkinson research from industry and US federal and foundation sources.

Dorsey ER, Thompson JP, Frasier M, Sherer T, Fiske B, Nicholson S, Johnston SC, Holloway RG, Moses H 3rd.

Mov Disord. 2009 Apr 15;24(5):731-7. doi: 10.1002/mds.22446.

PMID:
19133662
[PubMed - indexed for MEDLINE]
7.

How to create innovation by building the translation bridge from basic research into medicinal drugs: an industrial perspective.

Germann PG, Schuhmacher A, Harrison J, Law R, Haug K, Wong G.

Hum Genomics. 2013 Mar 5;7:5. doi: 10.1186/1479-7364-7-5.

PMID:
23496921
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Guidelines, editors, pharma and the biological paradigm shift.

Singh AR, Singh SA.

Mens Sana Monogr. 2007 Jan;5(1):27-30. doi: 10.4103/0973-1229.32176.

PMID:
22058616
[PubMed]
Free PMC Article
9.

[Financial conflict of interest in clinical psychiatry studies: a review].

Ulaş H, Binbay T, Alptekin K.

Turk Psikiyatri Derg. 2008 Winter;19(4):418-26. Review. Turkish.

PMID:
19110984
[PubMed - indexed for MEDLINE]
Free Article
10.

New strategies for innovation in global health: a pharmaceutical industry perspective.

Witty A.

Health Aff (Millwood). 2011 Jan;30(1):118-26. doi: 10.1377/hlthaff.2010.0933.

PMID:
21209447
[PubMed - indexed for MEDLINE]
Free Article
11.

The responsibility of the pharmaceutical industry.

Durrant C.

Clin Microbiol Infect. 2001;7 Suppl 6:2-4.

PMID:
11990688
[PubMed - indexed for MEDLINE]
12.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
[PubMed - indexed for MEDLINE]
13.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd.

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
[PubMed - indexed for MEDLINE]
14.

Discovery of innovative therapeutics: today's realities and tomorrow's vision. 1. Criticisms faced by the pharmaceutical industry.

Abou-Gharbia M, Childers WE.

J Med Chem. 2013 Jul 25;56(14):5659-72. doi: 10.1021/jm400330j. Epub 2013 Apr 29.

PMID:
23557017
[PubMed - indexed for MEDLINE]
15.

New Zealand's pharmaceutical reference-pricing strategy may backfire.

Menkes D.

Lancet. 2000 Feb 12;355(9203):558. No abstract available.

PMID:
10683017
[PubMed - indexed for MEDLINE]
16.

Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.

Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal B, Shi L.

Value Health. 2010 Jan-Feb;13(1):3-7. doi: 10.1111/j.1524-4733.2009.00663.x. Epub 2009 Oct 28.

PMID:
19874571
[PubMed - indexed for MEDLINE]
17.

Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study.

Lundh A, Barbateskovic M, Hróbjartsson A, Gøtzsche PC.

PLoS Med. 2010 Oct 26;7(10):e1000354. doi: 10.1371/journal.pmed.1000354. Erratum in: PLoS Med. 2011 Feb;8(2). doi: 10.1371/annotation/7e5c299c-2db7-4ddf-8eff-ab793511eccd.

PMID:
21048986
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Returns to R&D on new drug introductions in the 1980s.

Grabowski HG, Vernon JM.

J Health Econ. 1994 Dec;13(4):383-406. Review.

PMID:
10140531
[PubMed - indexed for MEDLINE]
19.

Open access chemical and clinical probes to support drug discovery.

Edwards AM, Bountra C, Kerr DJ, Willson TM.

Nat Chem Biol. 2009 Jul;5(7):436-40. doi: 10.1038/nchembio0709-436.

PMID:
19536100
[PubMed - indexed for MEDLINE]
20.

Does managed care fuel pharmaceutical industry growth?

Murray MD, Deardorff FW.

Pharmacoeconomics. 1998 Oct;14(4):341-8.

PMID:
10344902
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk